Alfuzosin and Silodosin interaction
Alfuzosin and Silodosin: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Alfuzosin (Uroxatral) label · effective 2024-12-05
Should not be used in combination with other alpha adrenergic antagonists ( 5.4 , 7.2 )
Other alpha adrenergic antagonists: UROXATRAL is an alpha adrenergic antagonist and should not be used in combination with other alpha adrenergic antagonist [see Drug Interactions (7.2) ].
However, interactions may be expected, and UROXATRAL should not be used in combination with other alpha adrenergic antagonists [see Warnings and Precautions (5.4) ].
As with other alpha adrenergic antagonists, there is a potential for syncope.
Priapism Rarely (probably less than 1 in 50,000), alfuzosin, like other alpha adrenergic antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity).
From the Silodosin label · effective 2026-03-16
Silodosin capsules should not be used in combination with other alpha-blockers.
However, interactions may be expected, and silodosin capsules should not be used in combination with other alpha-blockers [see DRUG INTERACTIONS (7.3) ].
As with other alpha-blockers, there is potential for syncope.
Pharmacodynamic Drug-Drug Interactions The pharmacodynamic interactions between silodosin and other alpha-blockers have not been determined.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.